GSK Annual Report 2002

Consolidated statement of profit and loss GlaxoSmithKline 77
2001 2000
Merger, Merger,
restructuring restructuring
Business and disposal Business and disposal
performance of subsidiaries Statutory performance of subsidiaries Statutory
(restated) (restated) (restated) (restated (restated) (restated)
£m £m £m £m £m £m
20,489 – 20,489 18,079 – 18,079
(4,430) (303) (4,733) (3,811) (151) (3,962)
16,059 (303) 15,756 14,268 (151) 14,117
(7,451) (957) (8,408) (6,732) (404) (7,136)
(2,555) (96) (2,651) (2,510) (16) (2,526)
6,053 (1,356) 4,697 5,026 (571) 4,455
37 – 37 274 – 274
6,090 (1,356) 4,734 5,300 (571) 4,729
71 – 71 65 (8) 57
96 – 96 144 – 144
– – – – 1,416 1,416
– – – – (121) (121)
– (296) (296) – (14) (14)
6,257 (1,652) 4,605 5,509 702 6,211
(88) – (88) (182) – (182)
6,169 (1,652) 4,517 5,327 702 6,029
(1,655) 322 (1,333) (1,497) (250) (1,747)
4,514 (1,330) 3,184 3,830 452 4,282
(97) – (97) (120) – (120)
(34) – (34) (56) – (56)
4,383 (1,330) 3,053 3,654 452 4,106
– 50.3p – 67.7p
72.3p – 60.2p –
– 49.9p – 66.9p
3,053 4,106
(2,356) (2,097)
697 2,009
2001 2000
(restated) (restated)
£m £m
3,053 4,106
(151) (23)
– 16
– –
2,902 4,099